Compare DexCom, Inc. (DXCM) vs Invesco NASDAQ 100 ETF (QQQM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Invesco NASDAQ 100 ETF — how do they compare? DexCom, Inc. trades at $77.3 (market cap $28.06B), while Invesco NASDAQ 100 ETF trades at $291.76. The key difference: Invesco NASDAQ 100 ETF is trading nearer its 52-week high, DexCom, Inc. nearer its low. Which is the better fit depends on your goals.
| DXCM | QQQM | |
|---|---|---|
Market Cap | $28.06B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $89.53 | $307.23 |
52-Week Low | $54.84 | $228.02 |
Enterprise Value | $27.03B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
QQQM, the Invesco NASDAQ 100 ETF, trades at $292.69, down 1.22% for the day, with technical indicators showing a neutral to bearish bias. The fund provides concentrated exposure to mega-cap U.S. growth and technology companies, benefiting from AI infrastructure spending but facing stretched valuations and rising competition. Recent news highlights a fee war in the Nasdaq 100 ETF category and the inclusion of SpaceX into the underlying index, which may modestly impact the fund's composition.
The outlook for QQQM is balanced between structural growth drivers in technology and AI and near-term valuation and competitive risks. The investment opportunity lies in low-cost, diversified access to leading innovators, while key risks include sector concentration, potential slowing AI growth, and the fund's sensitivity to a narrow group of high-multiple stocks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Invesco NASDAQ 100 ETF
QQQM is an ETF designed to track the performance of the NASDAQ-100 Index. It provides exposure to the 100 largest non-financial companies listed on the NASDAQ. Positioned as a lower-cost and more long-term-investor-friendly alternative to its peer QQQ, QQQM offers the same fundamental market exposure but typically has a lower share price and is structured to appeal to investors focused on accumulation rather than active trading.
Read more on QQQM →
